RightFit
RecruitingNot applicable

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests radiation given in larger doses over a shorter time to treat lung cancer that has spread nearby. It is for adults with cancer in the chest who plan to get radiation and cancer medicines at the same time. Treatment depends on the tumor’s size and location.

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Age 18 or older.
  • Cancer in the chest confirmed by a tissue or cell test, including small cell or non-small cell lung cancer.
  • Plan to get radiation in separate doses totaling 60–66 Gy (a measure of radiation dose), along with cancer medicines.
  • Able to care for yourself and be up and about for at least half of your waking hours.
  • Have a PET/CT or CT scan of the chest.
  • Able to understand the study and willing to personally sign the approved consent form.
  • Expected to live at least 12 weeks.

Who can't join

  • Your cancer doctors decide that radiation or cancer medicines would not be safe for you.
  • You are younger than 18.
  • You have interstitial pulmonary fibrosis, a disease that scars the lungs.
  • You had chest radiation before, and the new high-dose treatment areas would overlap with the earlier ones.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Histologically or cytologically documented malignancy of the thorax including but not limited to non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy * ECOG performance status of 0-2 * PET/CT or CT Imaging of Thorax * Age ≥ 18 years old * Ability to understand and the willingness to personally sign the written IRB approved informed consent document * Estimated life expectancy of 12 weeks or longer Exclusion Criteria: * Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist * Age \< 18 years old * Diagnosis of interstitial pulmonary fibrosis * Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Study sites (2)

CA